Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "ASH"

1984 News Found

Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects
People | July 14, 2025

Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects

Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.


Sigachi updates on fire accident at its Pashamylaram Facility, Telangana
News | July 04, 2025

Sigachi updates on fire accident at its Pashamylaram Facility, Telangana

The company has confirmed that the deceased are 39


Ashland expands viatel bioresorbable polymers offering for medical devices
Medical Device | June 26, 2025

Ashland expands viatel bioresorbable polymers offering for medical devices

Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants


Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash
Diagnostic Center | May 22, 2025

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8


Neuberg Diagnostics and Star Imaging form JV for Maharashtra’s largest integrated diagnostics network
News | May 22, 2025

Neuberg Diagnostics and Star Imaging form JV for Maharashtra’s largest integrated diagnostics network

For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune


Supriya Lifescience inaugurates Rs. 125 crore new API production block in Maharashtra
News | December 17, 2024

Supriya Lifescience inaugurates Rs. 125 crore new API production block in Maharashtra

The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL


Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting
Diagnostic Center | November 07, 2024

Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM


USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington
Drug Approval | September 11, 2024

USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington

Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding